← Back to Search

Anti-migraine agent

Ubrogepant for Migraine

Phase 3
Recruiting
Research Sponsored by AbbVie
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Have experienced migraine attacks in at least 2 of 3 perimenstrual periods (PMPs) during the screening period.
At least a 1-year history of migraine with or without aura.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 68 weeks
Awards & highlights

Summary

This trial aims to study the safety and effectiveness of a new drug called ubrogepant in treating menstrual migraines. Menstrual migraines are headaches that occur before, during, or after

Who is the study for?
This trial is for adult females with a history of migraine, specifically menstrual migraine. Participants should have regular menstrual cycles and experience migraines during their period in at least two out of three cycles. They must be able to record daily diary data and have had less than 15 headache days per month.
What is being tested?
The study tests Ubrogepant's safety and effectiveness against placebo in preventing menstrual migraines. Around 450 women will take oral ubrogepant or placebo starting three days before their estimated menses for seven days, over three menstrual periods in the initial phase.
What are the potential side effects?
Possible side effects include typical drug reactions such as nausea, drowsiness, dry mouth, or more serious ones like allergic reactions. The exact side effects will be monitored through medical assessments and questionnaires.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have had migraine attacks during my period in at least 2 of the last 3 cycles.
Select...
I have had migraines for at least a year.
Select...
I have fewer than 15 headache days a month.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 68 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 68 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change From Baseline in Number of Migraine Days Occurring During Perimenstrual Period (PMP)
Number of Participants With Adverse Events (AEs)
Secondary outcome measures
Change From Baseline in Acute Medication Use Days During the Perimenstrual Period (PMP)
Change From Baseline in Number of Headache Days Occurring During Perimenstrual Period (PMP)
Change From Baseline in Number of Migraine Days With Moderate or Severe Headache During Perimenstrual Period (PMP)
+4 more

Trial Design

3Treatment groups
Experimental Treatment
Group I: Open-Label Extension Period: UbrogepantExperimental Treatment1 Intervention
Eligible participants from Double-Blind period may continue to receive ubrogepant during the open-label extension period.
Group II: Double-Blind Period: UbrogepantExperimental Treatment1 Intervention
Participants will receive ubrogepant during the double-blind period.
Group III: Double-Blind Period: Placebo for UbrogepantExperimental Treatment1 Intervention
Participants will receive placebo during the double-blind period.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ubrogepant
2016
Completed Phase 4
~4990

Find a Location

Who is running the clinical trial?

AbbVieLead Sponsor
1,004 Previous Clinical Trials
513,284 Total Patients Enrolled
11 Trials studying Migraine
8,621 Patients Enrolled for Migraine
ABBVIE INC.Study DirectorAbbVie
430 Previous Clinical Trials
155,648 Total Patients Enrolled
11 Trials studying Migraine
8,621 Patients Enrolled for Migraine
~300 spots leftby Sep 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top